Under combined clinical treatment with Bevacizumab and a tyrosine kinase inhibitor, lower amounts of S100A9-positive cells, and accordingly in non-small-cell lung cancer, a significant reduction in granulocytic MSDC, were also found in human blood samples, underlining the aforementioned preclinical findings [27,28]. Here, S100A9 is linked to non-small cell lung carcinoma.